Hence, dabrafenib and trametinib are recommended as one standard option for patients with completely resected stage III BRAF-mutated melanoma (level of evidence 1, grade of recommendation A).This treatment indication is not financed by the Spanish public health system, at the time of writing this document. This evidence concerns the gene BRAF and melanoma.